Talquetamab

SUSPENDED · PHASE1, PHASE2 · Extramedullary Disease in Multiple Myeloma, Multiple Myeloma

pending amendment

Scientific benefit, asset-specific safety, ownership and licensing: Unknown without reviewed evidence.

Detailed evidence is available in the local Pro plan simulation.